Dosimetric Comparison of Cesium-131 and Palladium-103 for Permanent Prostate Brachytherapy

Cancer types prostate

Authors

J.S. Musmacher, R.T. Byrnes, M. Ghaly, K. Satchwill, L. Rumpf

  • Published in journal:
International Journal of Radiation Oncology Biology Physics
November 1, 2007
Read at International Journal of Radiation Oncology Biology Physics

Related posts

Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point

Authors: R. Yaparpalvi, J. Rossinow, W.A. Cavanagh, W. Choi, L. Minsky, N. Kahan, W. Bodner, M. Garg, S. Kalnicki, C. Guha

Early Outcomes of Prostate Seed Implants with 131Cs: Toxicity and Initial PSA Dynamics from a Single Institution

Authors: C.S. Platta, D. Khuntia, J. Adkinson, E. Olson, S. Jennifer, H. Odau, R.R. Patel

Five Year Prostate-specific Antigen Outcomes after Caesium Prostate Brachytherapy

Authors: R.M. Benoit, R.P. Smith, S. Beriwal

Is there Decreased Duration of Acute Urinary and Bowel Symptoms after Prostate Brachytherapy with Cesium 131 Radioisotope?

Authors: S.G. DeFoe, S. Beriwal, R. Smith, R. Benoit

Perspective Therapeutics
Linkedin-in Youtube Vimeo
Perspective Therapeutics
Linkedin-in Youtube Vimeo

Company

Brachytherapy

Theranostics

Newsletter

Want to keep up-to-date on news and information?

Sign up
Sign up

Company

Newsletter

Want to keep up-to-date on news and information?

Sign up
Sign up

©2023. All rights reserved. Terms & Privacy | Privacy Policy

Scroll to top